Pasatru reports zero new HO lesions in OPTIMA extension
Regeneron said adult FOP patients in the OPTIMA trial extension had zero new heterotopic ossification lesions.
Story updates
04:11:21 PM UTC
SquawkNews
Pasatru is the first and only FDA-approved treatment demonstrating reductions in both new HO lesions and clinician-assessed flare-ups, per results of a 56-week placebo-controlled trial in adults with FOPLate-breaking data presented at ASBMR show sustained efficacy of Pasatru and a consistent safety…